

Supplementary Table 2. Prescription status of study participants at baseline

Variable	EXE group (n=21)	CON group (n=14)	P value
Metformin	17 (81.0)	12 (85.7)	0.714
SU	8 (38.1)	5 (35.7)	0.886
TZD	2 (9.5)	1 (7.7)	0.805
DPP4 inhibitors	9 (42.9)	5 (35.7)	0.672
Insulin	5 (23.8)	3 (21.4)	0.869
RAS inhibitors	18 (85.7)	11 (78.6)	0.582
Lipid lowering agents	13 (61.9)	8 (57.1)	0.778
Antiplatelet agents	6 (28.6)	5 (35.7)	0.656

Values are presented as number (%). Data were analyzed using chi-square test.

EXE, exercise group; CON, control group; SU, sulfonylurea; TZD, thiazolidinedione; DPP4, dipeptidyl peptidase 4; RAS, renin-angiotensin system.